Dysphagia. Impact on quality of life after radio(chemo)therapy of head and neck cancer.
BACKGROUND
In the past, xerostomia was considered one of the most important determining factors of quality of life (QoL) after radiotherapy (RT) of the head and neck region. In addition, more recent studies have shown that RT-induced dysphagia has an essential influence on the QoL.


METHODS
Between September 2005 and August 2007, 35 patients with locally advanced squamous cell carcinoma of the head and neck region were included in the prospective study. Patients were treated by IMAT (intensity-modulated arc therapy) or IMRT (intensity-modulated radiotherapy) planned on 3D imaging. A total of 28 patients (80%) received concomitant chemotherapy. The evaluation of QoL (EORTC QLQ-C30, H&N C-35) and toxicities (CTC 2.0) were assessed at the beginning of, during, and after RT as well as up to 12 months after the end of therapy.


RESULTS
At the end of therapy, 86% of the patients experienced difficulties in swallowing (62% CTC II-III°). Twelve months after the end of treatment, 15% still suffered from dysphagia CTC II-III°. Concomitant chemotherapy exacerbated the incidence and gravity of dysphagia, resulting in increasing dietary problems. QoL (EORTC) was significantly affected by dysphagia. In particular, the global state of health and QoL were influenced at the end of treatment (p=0.033) and at a later stage (p=0.050).


CONCLUSIONS
The findings of this study suggest that more emphasis should be placed on structured clinical diagnostics, therapy, and rehabilitation of deglutition problems. This means in particular to not only spare the parotids while planning the irradiation, but also to take into consideration the important structures for deglutition, like the retropharyngeal muscles.
Department of Radiotherapy, Regensburg University Medical Center, Regensburg, Germany. julia.maurer@klinik.uni-regensburg.de
Julia
J
Maurer
Matthias
M
Hipp
Christof
C
Schäfer
Oliver
O
Kölbl
D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology / Q000523:psychology / Q000532:radiotherapy*; D059186:Chemoradiotherapy, Adjuvant / Q000009:adverse effects; D003680:Deglutition Disorders / Q000523:psychology* / Q000534:rehabilitation; D005500:Follow-Up Studies; D006801:Humans; D021621:Imaging, Three-Dimensional; D009367:Neoplasm Staging; D010039:Otorhinolaryngologic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000523:psychology / Q000532:radiotherapy*; D011446:Prospective Studies; D011788:Quality of Life / Q000523:psychology*; D011832:Radiation Injuries / Q000523:psychology* / Q000534:rehabilitation; D011879:Radiotherapy Dosage; D011880:Radiotherapy Planning, Computer-Assisted; D050397:Radiotherapy, Intensity-Modulated; D011795:Surveys and Questionnaires